USA flag logo/image

An Official Website of the United States Government

Company Information:

Name: Biotherm, Inc.
Address: 5301 Departure Drive
Raleigh, NC 27604
Located in HUBZone: No
Woman-Owned: No
Minority-Owned: No
URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $325,000.00 5
SBIR Phase II $2,249,999.00 4

Award List:

PORTABLE SYSTEM FOR CONTROL OF ANTICOAGULANT THERAPY

Award Year / Program / Phase: 1987 / SBIR / Phase I
Agency: HHS
Principal Investigator: Bruce J Oberhardt Phd
Award Amount: $50,000.00

PORTABLE SYSTEM FOR CONTROL OF ANTICOAGULANT THERAPY

Award Year / Program / Phase: 1988 / SBIR / Phase II
Agency: HHS
Principal Investigator: Bruce J Oberhardt Phd
Award Amount: $500,000.00
Abstract:
Biotherm, inc. proposes to design and develop a portable system, analogous to a hand-held glucose meter, to permit rapid, convenient blood coagulation testing on freshly drawnsamples from patients undergoing anticoagulant therapy. this cost-effective system would better help meet the needs of… More

RAPID FIBRINOGEN ASSAY FOR USE IN THROMBOLYTIC THERAPY

Award Year / Program / Phase: 1990 / SBIR / Phase I
Agency: HHS
Principal Investigator: Bruce J Oberhardt
Award Amount: $50,000.00

DRUG CHALLENGE ASSAY FOR USE IN THROMBOLYTIC THERAPY

Award Year / Program / Phase: 1991 / SBIR / Phase I
Agency: HHS
Principal Investigator: Oberhardt, Bruce J , Principal Investigator
Award Amount: $50,000.00

RAPID FIBRINOGEN ASSAY FOR USE IN THROMBOLYTIC THERAPY

Award Year / Program / Phase: 1992 / SBIR / Phase II
Agency: HHS
Principal Investigator: Bruce J Oberhardt
Award Amount: $500,000.00
Abstract:
An assay system for monitoring functional fibrinogen in patients undergoing thrombolytic therapy will be developed. this system will be based on a novel dry reagent assay technology that has recently been applied successfully to ptand activated ptt tests. introduction of a rapid, convenient,… More

DRUG CHALLENGE ASSAY FOR USE IN THROMBOLYTIC THERAPY

Award Year / Program / Phase: 1993 / SBIR / Phase II
Agency: HHS
Principal Investigator: Oberhardt, Bruce J , Principal Investigator
Award Amount: $500,000.00
Abstract:
A test system for rapid screening of patients prior to initiation of thrombolytic therapy will be developed. this system will be based on a novel dry reagent assay technology which recently has been applied successfully to pt and activated ptt tests. introduction of a rapid convenient test of… More

Rapid Monitoring of Antithrombin Agents

Award Year / Program / Phase: 1994 / SBIR / Phase I
Agency: HHS
Principal Investigator: Bruce Oberhardt
Award Amount: $75,000.00

Rapid Immunoassay for Acute Myocardial Injury Detection

Award Year / Program / Phase: 1995 / SBIR / Phase I
Agency: HHS
Principal Investigator: Bruce Oberhardt
Award Amount: $100,000.00
Abstract:
Phase I is directed at the development of a rapid and quantitative diagnostic immunoassay for acuteinjury. This immunoassay will utilize a proven dry chemistry test system incorporating a cardiac-spechemically conjugated to active-site inactivated coagulation factor Xa. The test principle… More

Rapid Monitoring of Antithrombin Agents

Award Year / Program / Phase: 1996 / SBIR / Phase II
Agency: HHS
Principal Investigator: Bruce Oberhardt
Award Amount: $749,999.00
Abstract:
A functional assay system for monitoring antithrombin drugs, such as recombinant hirudin andhirudin analogs, in patients will be developed. This assay system will be based on a novel dry reagentparamagnetic particle-based assay technology that has recently been applied successfully to wholeblood,… More